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Introduction {#bjo15394-sec-0009}
============

At present, the World Health Organization states that one in five women suffer from hypertension and almost half of mortality in women is caused by cardiovascular disease (CVD).[1](#bjo15394-bib-0001){ref-type="ref"}, [2](#bjo15394-bib-0002){ref-type="ref"} In the past decades, large cohort studies have consistently shown an increased association of CVD in women with a history of pre‐eclampsia compared with women with uncomplicated pregnancies.[3](#bjo15394-bib-0003){ref-type="ref"}, [4](#bjo15394-bib-0004){ref-type="ref"} This has led to a better understanding of female‐specific risk factors for developing CVD.[5](#bjo15394-bib-0005){ref-type="ref"}, [6](#bjo15394-bib-0006){ref-type="ref"} Pre‐eclampsia complicates 3--5% of first pregnancies and recurs in approximately 15% of subsequent pregnancies.[3](#bjo15394-bib-0003){ref-type="ref"}, [7](#bjo15394-bib-0007){ref-type="ref"}, [8](#bjo15394-bib-0008){ref-type="ref"} Common underlying risk factors such as obesity, dyslipidaemia, inflammatory pathways and endothelial dysfunction are thought to contribute to both CVD and pre‐eclampsia‐complicated pregnancies.[9](#bjo15394-bib-0009){ref-type="ref"}, [10](#bjo15394-bib-0010){ref-type="ref"}, [11](#bjo15394-bib-0011){ref-type="ref"}, [12](#bjo15394-bib-0012){ref-type="ref"} As pregnancy requires comprehensive physiological changes in the endocrine, respiratory and circulatory systems, a complicated pregnancy may reveal a predisposition to CVD and act as a 'stress test' identifying women at risk for future disease. Whether metabolic and cardiovascular changes induced by pre‐eclampsia independently create a higher risk of CVD remains unknown.

Some countries have recently started notifying formerly pre‐eclamptic women of their increased risks of CVD and advise women to actively test for modifiable risk factors at an early age.[13](#bjo15394-bib-0013){ref-type="ref"}, [14](#bjo15394-bib-0014){ref-type="ref"}, [15](#bjo15394-bib-0015){ref-type="ref"}, [16](#bjo15394-bib-0016){ref-type="ref"} Pre‐emptive screening, early recognition and treatment may prove to be useful in preventing long‐term morbidity and mortality.[1](#bjo15394-bib-0001){ref-type="ref"}

It is well known that women with pre‐eclampsia in their first pregnancy tend to have a milder variant or no disease in following pregnancies.[8](#bjo15394-bib-0008){ref-type="ref"} It is conceivable that women who experience multiple episodes of pre‐eclampsia fail to adjust to the physiological changes and physical stresses more than women with subsequent uncomplicated pregnancies. As not all women with pre‐eclampsia develop CVD later in life, the recurrence of disease may be a helpful indicator for the necessity of screening. Previous studies briefly mention an effect of multiple pre‐eclampsia‐affected pregnancies on the risk of future hypertension and CVD. Although several reviews have been conducted on the relationship between pregnancy outcome and CVD, to the best of our knowledge, no systematic review or meta‐analysis has been conducted on recurrent pregnancy complications and future lifetime cardiovascular risk. This study aims to evaluate all available evidence on the effect that recurrent pre‐eclampsia has on long‐term CVD risk compared with a single episode of pre‐eclampsia with subsequent uncomplicated pregnancy.

Methods {#bjo15394-sec-0010}
=======

Literature search {#bjo15394-sec-0011}
-----------------

Medline and Embase were searched (until 1 June 2017) using search terms for 'pre‐eclampsia', 'hypertension' and 'cardiovascular disease'. We restricted the search to various synonyms for 'recurrent', 'follow up', 'risk' and 'history', as many articles have been published on CVD after pre‐eclampsia. A detailed description of the search strategy can be found in the Supplementary material (Appendix [S1](#bjo15394-sup-0003){ref-type="supplementary-material"}). Reference lists of original and review articles were reviewed. Articles in languages other than English or Dutch were translated using Google Translate and included when translation quality was sufficient. Unpublished studies were not included. The core outcome set for CVD after pregnancy complications (COMET registration number 701) is currently being developed and could not be used for this systematic review. There was no patient or public involvement in the carrying out of this study.

Inclusion and exclusion criteria {#bjo15394-sec-0012}
--------------------------------

Inclusion criteria were as follows: (1) original articles; (2) studies that compared women with recurrent pre‐eclampsia to women with a single episode of pre‐eclampsia followed by uneventful pregnancies; (3) cerebrovascular accident (CVA), ischaemic heart disease (IHD), thromboembolism, atherosclerosis, heart failure, CVD mortality, hypertension or cardiovascular hospitalisation as outcome; (4) full‐length article available; (5) inclusion of more than ten women; and (6) adult population. Studies with a follow‐up duration of \< 1 year were excluded. We only included studies in which specific data on pre‐eclampsia could be subtracted.

Study selection and data extraction {#bjo15394-sec-0013}
-----------------------------------

Two reviewers (LB, and CS or AJM) independently reviewed the title/abstract of all potential studies. As most articles do not show data on recurrence in their respective abstracts, many were reviewed as full text. Disagreement was resolved by discussion and consensus; if needed, the opinion of a third reviewer was decisive. Authors of articles with a promising study set‐up but no data in association with recurrence of pre‐eclampsia were contacted through email and allotted 3 months for a response. Data were extracted from each paper independently and included all relevant study specifics (i.e. definition of pre‐eclampsia, follow‐up time, outcome measures).

Assessment of study quality and bias {#bjo15394-sec-0014}
------------------------------------

The methodological quality of studies was assessed using the Newcastle--Ottawa quality assessment Scale for cohort and case--control by two researchers (LB/AJM) independently. The Newcastle--Ottawa Scale uses a scoring system of three categories: selection, comparability and outcome (cohort studies) or exposure (case--control studies).[17](#bjo15394-bib-0017){ref-type="ref"} When a cohort study was based on one single cohort of women, the scale was adjusted accordingly. The Newcastle--Ottawa Scale scoring of each included study can be found in the Supplementary material (Table [S1](#bjo15394-sup-0002){ref-type="supplementary-material"}).

Statistics {#bjo15394-sec-0015}
----------

Incidence numbers were extracted from the data reported in each paper. When extracting hazard ratios (HR) and odds ratios (ORs), the most complete multivariate models were used to adjust for potential confounders. Most studies compared single or multiple occurrence pre‐eclampsia‐affected women to women without any complicated pregnancies, without making a comparison between the two affected groups. All hazard ratios described below are in comparison with women with solely uncomplicated pregnancy. We performed a meta‐analysis to give a direct overview of the risk when comparing the groups among themselves. [reviewmanager]{.smallcaps} 5.3.5 was used to calculate pooled risk ratios (RR) with 95% CI using a random‐effects model. To measure the amount of between‐study variation that is due to systematic heterogeneity rather than chance, the *I* ^2^ metric was used. We used the MOOSE checklist and PRISMA guidelines for this systematic review.[18](#bjo15394-bib-0018){ref-type="ref"}, [19](#bjo15394-bib-0019){ref-type="ref"}

This research did not receive any specific grant from funding agencies in the public, commercial or not‐for‐profit sectors.

Results {#bjo15394-sec-0016}
=======

Characteristics of the studies {#bjo15394-sec-0017}
------------------------------

We identified 22 studies for this review, a detailed description of the selection process can be found in the Supplementary material (Figure [S1](#bjo15394-sup-0001){ref-type="supplementary-material"}). Tables [1](#bjo15394-tbl-0001){ref-type="table"} and [2](#bjo15394-tbl-0002){ref-type="table"} summarise the characteristics of the studies included for hypertension and cardiovascular morbidity and mortality, respectively. There was a large variance in sample sizes (28--1 108 581) and study populations were selected from all over the world with a majority from northwest Europe, Canada and the USA. Follow up ranged from 1 to 45 years. Most studies used the American Congress of Obstetricians and Gynecologists criteria to identify women with pre‐eclampsia. The definition of hypertension as an outcome varied between measured mean blood pressure, antihypertensive treatment, hospital diagnosis, International Classification of Diseases (ICD) coding and self‐reported disease or treatment. When looking at cardiovascular morbidity and mortality, the majority of studies used record linkage through ICD codes and death certificates.

###### 

Characteristics and outcomes of studies about recurrent pre‐eclampsia in association with hypertension

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year published                                         Country, baseline years study   Study design   Exposure                             Definition of pre‐eclampsia                                    Definition of outcome                                                  No. of participants in study                                                             Follow‐up time (median, range) (years)   Age at follow up (median, range) (years)   Outcome[b](#bjo15394-note-0004){ref-type="fn"}                  
  -------------------------------------------------------------- ------------------------------- -------------- ------------------------------------ -------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------ --------------------------------------------------------------- ---------------------------------------------------------------------
  Singh, 1974[36](#bjo15394-bib-0036){ref-type="ref"}            UK, NS                          RCS            Severe PE                            NS                                                             NS                                                                     Mean BP (mmHg)                                                                           147                                      17.8                                       40                                                              sPE 137 (1.9)/87 (1.2)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        rPE 152 (3.9)/92 (2.8)

  Sibai, 1986[24](#bjo15394-bib-0024){ref-type="ref"}            USA, NS                         RCS            Severe PE/E                          \> 160, \>110                                                  \> 1 g/24 hr                                                           Antihypertensive medication                                                              815                                      6.6                                        30.9                                                            OR 7.4 (NS)

  Sibai, 1991[38](#bjo15394-bib-0038){ref-type="ref"}            USA, NS                         RCS            Severe PE\                           NS                                                             NS                                                                     Antihypertensive medication                                                              125                                      5.4                                        NS                                                              OR 10.7 (NS)
                                                                                                                (2nd trimester)                                                                                                                                                                                                                                                                                                                                                                                                         

  Nisell, 1995[30](#bjo15394-bib-0030){ref-type="ref"}           Sweden 986                      RCS            PIH/PE                               \>140, \>90                                                    \>0.3 g/24 hr                                                          Antihypertensive medication OR two measurements of DBP ≥90 mmHg with a 15‐min interval   138                                      7                                          NS                                                              Incidence\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        sPE 21%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        rPE 25%

  Gaugler‐Senden, 2008[27](#bjo15394-bib-0027){ref-type="ref"}   The Netherlands 1993--2003      CCS            Severe PE/E/HELLP (GA \< 24 weeks)   NS, \>110\                                                     2+ (1 g/l)                                                             \>140 and/or \>90 mmHg, and/or use of antihypertensive medication                        40                                       5.5                                        38.8                                                            NS
                                                                                                                                                     \>140,\>90                                                                                                                                                                                                                                                                                                                                                                         

  Lykke, 2009[21](#bjo15394-bib-0021){ref-type="ref"}            Denmark 1978--2007              RCS            PE/E/HELLP                           ACOG criteria                                                  ICD‐8/ICD‐10: DI10--13, DI15, 400--404                                 536.419                                                                                  12.9                                     42.6                                       sPE HR 2.7 (2.5--2.9)[a](#bjo15394-note-0003){ref-type="fn"}\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        rPE HR 6.0 (5.4--6.7)[a](#bjo15394-note-0003){ref-type="fn"}    

  Magnussen, 2009[22](#bjo15394-bib-0022){ref-type="ref"}        Norway 1967--1995               PCS            PE                                   \>140, \>90                                                    \>0.3 g/24 hr                                                          Mean BP (mmHg)                                                                           15.065                                   16.5                                       40.1                                                            sPE 132.2 (130.7--133.7)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        rPE 136.7 (133.6--139.9)

  Antihypertensive medication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  sPE OR 3.1 (2.2--4.3)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  rPE OR 11.6 (7.1--26.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Smith, 2009[28](#bjo15394-bib-0028){ref-type="ref"}            Canada, NS                      PCS            PE                                   \>140 \>90                                                     \>0.3 g/24 hr\                                                         Mean BP (mmHg)                                                                           70                                       1                                          NS                                                              NS
                                                                                                                                                                                                                    ≥2 on dipstick                                                                                                                                                                                                                                                                                                      

  Spaan, 2012[39](#bjo15394-bib-0039){ref-type="ref"}            The Netherlands\                RCS            PE                                   \>140, \>90                                                    \>0.3 g/24 hr                                                          Self‐reported use of antihypertensive medication                                         339                                      6                                          NS                                                              HR 4.3 (1.6--11.5)
                                                                 1996--2010                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  van Oostwaard, 2012[40](#bjo15394-bib-0040){ref-type="ref"}    The Netherlands\                RCS            PIH/PE/HELLP preterm                 \>140, \>90                                                    \>0.3 g/24 hr                                                          Self‐reported chronic hypertension                                                       189                                      8.5                                        NS                                                              RR 2.4 (1.0--5.4)[c](#bjo15394-note-0005){ref-type="fn"}
                                                                 2000--2002                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Ghossein‐Doha, 2014[32](#bjo15394-bib-0032){ref-type="ref"}    The Netherlands, 1996--1999     NCCS           PE                                   \>140, \>90                                                    \>0.3 g/24 hr                                                          BP ≥ 140/90 mmHg                                                                         28                                       14                                         43                                                              Incidence\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        sPE 22%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        rPE 86%

  van Oostwaard, 2014[41](#bjo15394-bib-0041){ref-type="ref"}    The Netherlands\                RCS            PIH/PE/HELLP term                    \>140, \>90                                                    \>0.3 g/24 hr                                                          Self‐reported chronic hypertension                                                       120                                      11                                         NS                                                              RR 1.8 (1.1--3.0)[c](#bjo15394-note-0005){ref-type="fn"}
                                                                 2000--2002                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Engeland, 2015[20](#bjo15394-bib-0020){ref-type="ref"}         Norway 1967--2012               PCS            PE/E/HELLP                           \>140, \>90                                                    \>0.3 g/24 hr                                                          Antihypertensive medication                                                              978.493                                  46                                         NS                                                              sPE HR 2.0 (2.0--2.0)[a](#bjo15394-note-0003){ref-type="fn"}\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        rPE HR 2.8 (2.7--3.0)[a](#bjo15394-note-0003){ref-type="fn"}

  Scholten, 2015[35](#bjo15394-bib-0035){ref-type="ref"}         The Netherlands\                PCS            PE                                   \>140, \>90                                                    \>0.3 g/24 hr                                                          BP ≥ 140/90 mmHg                                                                         104                                      4.6                                        36                                                              Incidence sPE 15.9%\
                                                                 2008--2010                                                                                                                                                                                                                                                                                                                                                                                                                                                             rPE 27.8%

  Veerbeek, 2015[37](#bjo15394-bib-0037){ref-type="ref"}         The Netherlands\                PCS            PE/PIH                               \>140 \>90                                                     \>0.3 g/24 hr\                                                         Mean BP (mmHg)                                                                           152                                      2‐5                                        31‐34                                                           sPE 124.2 (13.2)/81.9 (9.4)[c](#bjo15394-note-0005){ref-type="fn"}\
                                                                 2008--2010                                                                                                                                         ≥2 on dipstick                                                                                                                                                                                                                                                                                                      rPE 123.7 (18.3)/83.8 (12.6)[c](#bjo15394-note-0005){ref-type="fn"}

  Zhang, 2015[34](#bjo15394-bib-0034){ref-type="ref"}            China 2009--2013                PCS            PE/E/superimposed PE                 NS                                                             NS                                                                     NS                                                                                       115                                      5                                          NS                                                              Incidence\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        sPE 23.3%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        rPE 47.5%

  Auger, 2017[26](#bjo15394-bib-0026){ref-type="ref"}            Canada 1989--2013               PCS            PE                                   ICD‐9: 642.3, 642.4, O13, 642.5, 642.6, O14, O15, 642.7, O11   ICD‐9: 401--405, 416.8, 437.2, 461.0, ICD‐10: I10--I15, I27.0, I67.4   1.108.581                                                                                14.5                                     NS                                         sPE HR 3.7 (3.5--3.9)[a](#bjo15394-note-0003){ref-type="fn"}\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        rPE HR 7.2 (6.6--7.8)[a](#bjo15394-note-0003){ref-type="fn"}    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BP, blood pressure; CCS, case--control study; CH, chronic hypertension; DBP, diastolic blood pressure (mmHg); E, eclampsia; GA, gestational age; HT, hypertension; HELLP, haemolysis elevated liver enzymes low platelets syndrome; NCCS, nested case--control study; PCS, prospective cohort study; PE, pre‐eclampsia; PIH, pregnancy‐induced hypertension; rPE, women with recurrent pre‐eclampsia; RCS: retrospective cohort study; SBP, systolic blood pressure (mmHg); sPE, women with one pregnancy with pre‐eclampsia and normal subsequent pregnancy.

NS: data not shown or specified.

Hazard ratio in comparison with women without any complicated pregnancies.

Outcome is specified in either odds ratio, hazard ratio or risk ratio with a 95% confidence interval or mean blood pressure (mmHg) with standard deviation or 95% confidence interval as presented in the corresponding study.

Numbers or data received from the author.

John Wiley & Sons, Ltd

###### 

Characteristics and outcomes of studies about recurrent pre‐eclampsia in association with cardiovascular morbidity and mortality

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year published                                        Country, baseline years study                                                             Study design                                                     Exposure   Definition of pre‐eclampsia                                    Outcome          Definition of outcome                         No. of participants in study                                                                                                           Follow‐up time (median, range) (years)   Age at follow up (median, range) (years)   Outcome[b](#bjo15394-note-0009){ref-type="fn"}                   
  ------------------------------------------------------------- ----------------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------- -------------------------------------------------------------- ---------------- --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------ ---------------------------------------------------------------- ----------------------------------------------------------------
  Lykke, 2009[21](#bjo15394-bib-0021){ref-type="ref"}           Denmark\                                                                                  RCS                                                              PE/E/\     ACOG criteria                                                  IHD              ICD‐9: 410--414, ICD‐10: i20--i25             536 419                                                                                                                                12.9                                     NS                                         sPE: HR 1.3 (1.1--1.5)[a](#bjo15394-note-0008){ref-type="fn"}\   
                                                                1978--2007                                                                                                                                                 HELLP                                                                                                                                                                                                                                                                                                                                                               rPE: HR 2.8 (2.3--3.4)[a](#bjo15394-note-0008){ref-type="fn"}    

  HF                                                            ICD‐8: 42709--42711, 42719, 42799, 42899, 42900, 42908, 42909, ICD‐10: i50, i513, i519,   sPE: HR 1.3 (1.0--1.7)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 2.4 (1.6--3.5)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  TE                                                            ICD‐9: 444, 450, 451, ICD‐10: i26, i74, i82.                                              sPE: HR 1.3 (1.1--1.6)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 1.8 (1.3--2.5)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CVA                                                           ICD‐10: i60--i67, g45. ICD‐8: 430--438                                                    sPE: HR 1.2 (1.1--1.4)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 1.5 (1.2--1.9)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Skjaerven, 2012[25](#bjo15394-bib-0025){ref-type="ref"}       Norway\                                                                                   PCS                                                              PE         \>140, \>90                                                    \>0.3 g/24 hr    CVD death                                     ICD‐8/9: 390--459, 410--414, 430--438\                                                                                                 700 400                                  7--42                                      NS                                                               sPE: HR 1.5 (1.2--1.9)[a](#bjo15394-note-0008){ref-type="fn"}\
                                                                1967--2002                                                                                                                                                                                                                                                                                          ICD‐10 i00--i99, i20--i25, i60--69.                                                                                                                                                                                                                                                         rPE: HR 2.3 (1.5--3.6)[a](#bjo15394-note-0008){ref-type="fn"}

  Akhter, 2014[31](#bjo15394-bib-0031){ref-type="ref"}          Sweden, NS                                                                                CCS                                                              PE         \>140, \>90                                                    \>0.3 g/24 hr\   Atherosclerosis                               Carotid artery intima‐media thickness measurements using ultrasound                                                                    42                                       NS                                         40--50                                                           NS
                                                                                                                                                                                                                                                                                                     ≥2 on dipstick                                                                                                                                                                                                                                                                                                                                             

  Kessous, 2015[33](#bjo15394-bib-0033){ref-type="ref"}         Israel\                                                                                   RCS                                                              PE         NS                                                                              Simple cardiovascular events                  ICD‐9 4149, 4292, 4438, 4139, 44389, 436, 437, 413, 4371, 4118, 41181, 2722, 2724, 402, 411, 414, 4148, 4299, 440, 4402, 4019, 4439)   1182                                     0--24                                      NS                                                               Incidence\
                                                                1988--2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      sPE 1.6%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                rPE 2.2%

  Complex cardiovascular events                                 ICD 9 codes 410, 4280, 4281, 4289, 4280, 404, 4049, 4275, 415, 4150                       Incidence\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                          rPE 2.7%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                          rPE 4.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Cardiovascular hospitalisation                                NS                                                                                        Incidence\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                          sPE 4.4%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                          rPE 6.0%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Auger, 2016[26](#bjo15394-bib-0026){ref-type="ref"}           Canada\                                                                                   PCS                                                              PE         ICD‐9: 642.3, 642.4, O13, 642.5, 642.6, O14, O15, 642.7, O11   CVD overall      ICD‐9: 401--445, 447--453, ICD‐10: i10--i82   606 820                                                                                                                                16                                       NS                                         sPE: HR 2.3 (2.2--2.4)[a](#bjo15394-note-0008){ref-type="fn"}\   
                                                                1989--2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     rPE: HR 3.9 (3.6--4.2)[a](#bjo15394-note-0008){ref-type="fn"}    

  IHD                                                           ICD‐9: 410--414, ICD‐10: i20--i25                                                         sPE: HR 1.9 (1.7--2.2)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 3.3 (2.6--4.2)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CVA                                                           ICD‐9: 433--438 ICD‐10: I63--I66.9, I67.2                                                 sPE: HR 1.6 (1.4--1.9)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 3.0 (2.3--4.1)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Atherosclerosis                                               ICD‐9:414.0, 414.3, 414.4, 429.2, 440, ICD‐10: i25.0, i25.1, i70                          sPE: HR 2.1 (1.8--2.5)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 4.0 (3.0--5.3)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  DVT                                                           ICD‐9: 451.1, 451.83, 453.4--453.5, 453.72, 453.82, ICD‐10: i80.1--i80.3                  sPE: HR 1.7 (1.3--2.1)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 1.3 (0.7--2.3)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Pulmonary embolism                                            ICD‐9: 415.1, ICD‐10: I26                                                                 sPE: HR 1.2 (1.0--1.5)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 1.4 (0.9--2.1)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  HF                                                            ICD‐9: 428, ICD‐10: i50                                                                   sPE: HR 2.0 (1.6--2.5)[a](#bjo15394-note-0008){ref-type="fn"}\                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          rPE: HR 4.2 (2.9--6.1)[a](#bjo15394-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Ghossein‐Doha, 2017[29](#bjo15394-bib-0029){ref-type="ref"}   The Netherlands, NS                                                                       CSC                                                              PE         \>140 \>90                                                     \>0.3 g/24 hr    HF‐B\                                         Determined by cardiac ultrasound                                                                                                       107                                      4--10                                      36--40                                                           OR 2.0 (0.7--5.2)
                                                                                                                                                                                                                                                                                                                      (nonsymptomatic)                                                                                                                                                                                                                                                                                                                          

  Riise, 2017[23](#bjo15394-bib-0023){ref-type="ref"}           Norway\                                                                                   PCS                                                              PE         \>140, \>90                                                    \>0.3 g/24 hr    IHD                                           ICD‐9: 410--414, ICD‐10: i20--i25                                                                                                      281 069                                  18                                         NS                                                               sPE: HR 2.8 (1.7--4.6)[a](#bjo15394-note-0008){ref-type="fn"}\
                                                                1980--2002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      rPE: HR 4.7 (2.3--9.4)[a](#bjo15394-note-0008){ref-type="fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACOG, American college obstetrics and gynecology; CCS, case--control study; CSC, cross‐sectional cohort study; CVD, cardiovascular disease; DBP, diastolic blood pressure (mmHg); DVT, deep venous thrombosis; E, eclampsia; HELLP, haemolysis elevated liver enzymes low platelets syndrome; HF, heart failure; HF‐B, heart failure type B; HR, hazard ratio; ICD, international classification of disease; IHD, ischaemic heart disease; NS, data not shown/specified; OR, odds ratio; PCS, prospective cohort study; PE, pre‐eclampsia; RCS, retrospective cohort study; rPE, women with recurrent pre‐eclampsia; SBP, systolic blood pressure (mmHg); sPE, women with one pregnancy with pre‐eclampsia and normal subsequent pregnancy; TE, thromboembolism.

NS: data not shown or specified.

Hazard ratio in comparison with women without any complicated pregnancies.

Outcome is specified in either odds ratio or hazard ratio with 95% confidence interval or incidence (%) as presented in the corresponding study.

John Wiley & Sons, Ltd

Quality of evidence {#bjo15394-sec-0018}
-------------------

The quality score of the included studies can be found in the Supplementary material (Table [S1](#bjo15394-sup-0002){ref-type="supplementary-material"}). Six studies reached the respective maximum of stars among the cohort and case--control studies (maximum nine stars)[20](#bjo15394-bib-0020){ref-type="ref"}, [21](#bjo15394-bib-0021){ref-type="ref"}, [22](#bjo15394-bib-0022){ref-type="ref"}, [23](#bjo15394-bib-0023){ref-type="ref"}, [24](#bjo15394-bib-0024){ref-type="ref"}, [25](#bjo15394-bib-0025){ref-type="ref"}; three studies received eight stars,[26](#bjo15394-bib-0026){ref-type="ref"}, [27](#bjo15394-bib-0027){ref-type="ref"}, [28](#bjo15394-bib-0028){ref-type="ref"} two received seven,[29](#bjo15394-bib-0029){ref-type="ref"}, [30](#bjo15394-bib-0030){ref-type="ref"} four received six,[31](#bjo15394-bib-0031){ref-type="ref"}, [32](#bjo15394-bib-0032){ref-type="ref"}, [33](#bjo15394-bib-0033){ref-type="ref"}, [34](#bjo15394-bib-0034){ref-type="ref"} one received five[35](#bjo15394-bib-0035){ref-type="ref"} and one study obtained three stars.[36](#bjo15394-bib-0036){ref-type="ref"} For studies comparing a single cohort, one study received the maximum score of seven stars.[37](#bjo15394-bib-0037){ref-type="ref"} The remaining four studies received five of seven stars.[38](#bjo15394-bib-0038){ref-type="ref"}, [39](#bjo15394-bib-0039){ref-type="ref"}, [40](#bjo15394-bib-0040){ref-type="ref"}, [41](#bjo15394-bib-0041){ref-type="ref"}

Hypertension {#bjo15394-sec-0019}
------------

Overall, 17 papers were found to report on developing hypertension after recurrent pre‐eclampsia, details can be found in Table [1](#bjo15394-tbl-0001){ref-type="table"}. Four studies reported on mean blood pressure after variable lengths of follow up.[22](#bjo15394-bib-0022){ref-type="ref"}, [28](#bjo15394-bib-0028){ref-type="ref"}, [36](#bjo15394-bib-0036){ref-type="ref"}, [37](#bjo15394-bib-0037){ref-type="ref"} Two studies performed their analysis 1--5 years postpartum and did not find any difference between the groups.[28](#bjo15394-bib-0028){ref-type="ref"}, [37](#bjo15394-bib-0037){ref-type="ref"} Two studies followed women for almost two decades, finding a significant increase in mean blood pressure in the group with recurrent pre‐eclampsia.[22](#bjo15394-bib-0022){ref-type="ref"}, [36](#bjo15394-bib-0036){ref-type="ref"} Five studies found higher risk of antihypertensive medication use when pre‐eclampsia was recurrent compared with a single complicated pregnancy and when compared with women with uncomplicated pregnancy only.[20](#bjo15394-bib-0020){ref-type="ref"}, [22](#bjo15394-bib-0022){ref-type="ref"}, [24](#bjo15394-bib-0024){ref-type="ref"}, [38](#bjo15394-bib-0038){ref-type="ref"}, [39](#bjo15394-bib-0039){ref-type="ref"} Two smaller studies looked at the proportion of recurrent pre‐eclampsia in women who were hypertensive at follow up after having had pre‐eclampsia in the index pregnancy and found conflicting results.[32](#bjo15394-bib-0032){ref-type="ref"}, [35](#bjo15394-bib-0035){ref-type="ref"} Three studies observed women who went on to have subsequent pregnancies after pre‐eclampsia, in the first two articles a nonsignificant association was mentioned in the text.[27](#bjo15394-bib-0027){ref-type="ref"}, [30](#bjo15394-bib-0030){ref-type="ref"}, [34](#bjo15394-bib-0034){ref-type="ref"} One study found a higher incidence of hypertension among women with recurring pre‐eclampsia, although information on their study set‐up was limited.[34](#bjo15394-bib-0034){ref-type="ref"} Van Oostwaard et al.[40](#bjo15394-bib-0040){ref-type="ref"}, [41](#bjo15394-bib-0041){ref-type="ref"} published on the risk of hypertension in women with recurrent pregnancy‐induced hypertension or pre‐eclampsia. The author kindly shared data regarding pre‐eclampsia only, resulting in relatively small study groups. For women delivering at term (*n* = 74) and preterm (*n* = 59) there was a significantly higher chance of hypertension after recurrence of pre‐eclampsia compared with women with a normal subsequent pregnancy (RR 1.83; 95% CI 1.11--3.02 and RR 2.35; 95% CI 1.02--5.43, respectively). Two groups performed large registry‐based cohort studies with ICD codes comparing women with pre‐eclampsia with women with only nonhypertensive pregnancy.[21](#bjo15394-bib-0021){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"} One study showed a risk gradient, with a higher risk of hypertension after pre‐eclampsia in the first pregnancy (HR 2.70; 95% CI 2.51--2.90) compared with women with two or more normotensive pregnancies. The risk increased (HR 4.34; 95% CI 3.98--4.74) for women with pre‐eclampsia in their second pregnancy only, and increased again for women with pre‐eclampsia in both pregnancies (HR 6.00; 95% CI 5.40--6.67).[21](#bjo15394-bib-0021){ref-type="ref"} Auger et al.[26](#bjo15394-bib-0026){ref-type="ref"} reported increasing hazard ratios of 3.7 (95% CI 3.5--3.9) for a single episode of pre‐eclampsia and 7.2 (95% CI 6.6--7.8) for recurrent pre‐eclampsia when compared with women who only had normotensive pregnancies, 25 years after the index pregnancy.

### Meta‐analysis {#bjo15394-sec-0020}

Incidence data on 52 544 women could be extracted from seven studies to perform a meta‐analysis.[21](#bjo15394-bib-0021){ref-type="ref"}, [24](#bjo15394-bib-0024){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"}, [34](#bjo15394-bib-0034){ref-type="ref"}, [38](#bjo15394-bib-0038){ref-type="ref"}, [40](#bjo15394-bib-0040){ref-type="ref"}, [41](#bjo15394-bib-0041){ref-type="ref"} In the pooled analysis the risk ratio for hypertension after follow up was increased in women with recurrent pre‐eclampsia (pooled RR 2.33; 95% CI 1.86--2.92, Figure [1](#bjo15394-fig-0001){ref-type="fig"}.1.1). Heterogeneity between studies was considerable (*I* ^2^ = 82%), so a sensitivity analysis was performed. When excluding the largest study by Auger et al. from the pooled analysis, heterogeneity tested was lower (*I* ^2^ = 1%), nonetheless the found effect did not change (pooled RR 2.57; 95% CI 2.32--2.85).

![Forest plot of studies investigating the risk of hypertension (1.1.1), ischaemic heart disease (1.1.2), heart failure (1.1.3), cerebrovascular accident (1.1.4) and overall hospitalisation due to cardiovascular disease (1.1.5) after recurrent pre‐eclampsia when compared with women with a single pregnancy affected by pre‐eclampsia and subsequent normal pregnancy. Incidence data were extracted from original articles using available figures and tables. \*Original data provided by author was used.](BJO-125-1642-g001){#bjo15394-fig-0001}

Atherosclerosis {#bjo15394-sec-0021}
---------------

Two studies reported on atherosclerosis after recurrent pre‐eclampsia.[26](#bjo15394-bib-0026){ref-type="ref"}, [31](#bjo15394-bib-0031){ref-type="ref"} An ICD‐code for atherosclerosis was found to be significantly more present in the recurrent pre‐eclampsia group (HR 4.0; 95% CI 3.0--5.3) than in single affected women (HR 2.1; 95% CI 1.8--2.5) when compared with women with solely uncomplicated pregnancies.[26](#bjo15394-bib-0026){ref-type="ref"} Akhter et al. performed carotid artery intima‐media thickness measurements in 42 women with previous pre‐eclampsia. Although they found significantly higher intima‐media thickness for women who had pre‐eclampsia, they did not find a higher measurement when pre‐eclampsia had recurred.[31](#bjo15394-bib-0031){ref-type="ref"}

Thromboembolism {#bjo15394-sec-0022}
---------------

Two record‐linkage studies reported on various types of thrombosis after one or multiple pre‐eclampsia‐affected pregnancies compared with women with only uncomplicated pregnancy.[21](#bjo15394-bib-0021){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"} One study discusses both deep venous thrombosis and pulmonary embolism in one category showing increasing hazard ratios when pre‐eclampsia was recurrent.[21](#bjo15394-bib-0021){ref-type="ref"} Auger et al.[26](#bjo15394-bib-0026){ref-type="ref"} discussed results separately, finding higher hazard ratios for both outcomes when comparing single and recurrent pre‐eclampsia with women with uncomplicated pregnancies (Table [2](#bjo15394-tbl-0002){ref-type="table"}).

Ischaemic heart disease {#bjo15394-sec-0023}
-----------------------

Three record‐linkage studies reported on IHD after one or multiple pre‐eclampsia‐affected pregnancies compared with women with only uncomplicated pregnancies. Riise et al. reported an increasing hazard ratio after recurrence of pre‐eclampsia (HR 2.20; 95% CI 0.91--5.32 in recurrent pre‐eclampsia and HR 1.95; 95% CI 1.31--2.91 for a single pre‐eclampsia pregnancy), compared with unaffected pregnancies. When pre‐eclampsia was combined with fetal growth restriction or preterm birth the change in hazard ratio was more significant (HR 4.66; 95% CI 2.31--9.37 in recurrent pre‐eclampsia as opposed to one episode of pre‐eclampsia; HR 2.81; 95% CI 1.70--4.61).[23](#bjo15394-bib-0023){ref-type="ref"} The other two ICD‐coded studies showed a similar increase in hazard ratio when comparing women with single or multiple affected pregnancies with women without pregnancy complications (Table [2](#bjo15394-tbl-0002){ref-type="table"}).[21](#bjo15394-bib-0021){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"}

### Meta‐analysis {#bjo15394-sec-0024}

With all studies combined, 10 522 women who had recurrent pre‐eclampsia contributed to the meta‐analysis on IHD.[21](#bjo15394-bib-0021){ref-type="ref"}, [23](#bjo15394-bib-0023){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"} In the pooled analysis an increased risk of IHD was observed for recurrent pre‐eclampsia (RR 2.40; 95% CI 2.15--2.68; Figure [1](#bjo15394-fig-0001){ref-type="fig"}.1.2). Heterogeneity between the studies was low (*I* ^2^ = 0%).

Heart failure {#bjo15394-sec-0025}
-------------

Three studies described the development of heart failure. The two record‐linkage studies mentioned above indicated higher hazard ratios for recurrent pre‐eclampsia than for single pre‐eclampsia‐affected pregnancy compared with solely uncomplicated pregnancies (Table [2](#bjo15394-tbl-0002){ref-type="table"}).[21](#bjo15394-bib-0021){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"} Ghossein‐Doha et al.[29](#bjo15394-bib-0029){ref-type="ref"} reported on (nonsymptomatic) heart failure type‐B diagnosed by cardiac ultrasound 4--10 years postpartum. They did not find recurrence of pre‐eclampsia to be significantly associated with this type of heart failure (OR 2.0; 95% CI 0.7--5.2).

### Meta‐analysis {#bjo15394-sec-0026}

Due to the difference in outcome measures, only the data from two studies were comparable (Figure [1](#bjo15394-fig-0001){ref-type="fig"}.1.3).[21](#bjo15394-bib-0021){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"} In total, 9585 women had recurrent pre‐eclampsia and showed a pooled risk ratio 2.88 (95% CI 2.23--3.72). Heterogeneity was low (*I* ^2 ^= 27%).

Cerebrovascular accident {#bjo15394-sec-0027}
------------------------

The same two record‐linkage studies performed analysis on ischaemic and haemorrhagic CVA, finding higher adjusted hazard ratios for the women with recurrent pre‐eclampsia than women with a single pregnancy with pre‐eclampsia when compared with solely uncomplicated pregnancy (Table [2](#bjo15394-tbl-0002){ref-type="table"}).[21](#bjo15394-bib-0021){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"}

### Meta‐analysis {#bjo15394-sec-0028}

When results of both studies were combined a risk ratio of 1.69 (95% CI 1.21--2.35) was found with heterogeneity of 75% (Figure [1](#bjo15394-fig-0001){ref-type="fig"}.1.4).

Cardiovascular events and hospitalisation {#bjo15394-sec-0029}
-----------------------------------------

Kessous et al. performed a retrospective population study reporting on simple and complex cardiovascular events. Simple CVD events (i.e. hyperlipidaemia, hypertension) occurred significantly more in women with two or more pregnancies complicated by pre‐eclampsia (2.2% versus 1.6%; *P* = 0.001). Complex cardiovascular events (i.e. IHD, heart failure) occurred more frequently in the recurrent pre‐eclampsia group compared with women with one pre‐eclampsia‐affected pregnancy (4.6% versus 2.7%; *P* = 0.001). Patients were also admitted to the hospital more often due to CVD (6.0% versus 4.0%; *P* = 0.001).[33](#bjo15394-bib-0033){ref-type="ref"} This last outcome was also analysed in the record‐linkage study by Auger et al., finding a similar trend \[HR 3.9; 95% CI 3.6--4.2 (recurrent pre‐eclampsia) versus HR 2.3; 95% CI 2.2--2.4 (single pre‐eclampsia), compared with solely uncomplicated pregnancy\].[26](#bjo15394-bib-0026){ref-type="ref"}

### Meta‐analysis {#bjo15394-sec-0030}

When data were pooled for cardiovascular hospitalisations a pooled risk ratio of 1.57 (95% CI 1.31--1.90) was found with some heterogeneity (*I* ^2 ^= 60%, Figure [1](#bjo15394-fig-0001){ref-type="fig"}.1.5).

Cardiovascular mortality {#bjo15394-sec-0031}
------------------------

Only one study analysed the association between recurrent pre‐eclampsia and cardiovascular mortality. Even though they showed increasing hazard ratios for women with one, two or more pre‐eclampsia‐complicated pregnancies, there was no statistical significance when comparing the groups.[25](#bjo15394-bib-0025){ref-type="ref"}

Discussion {#bjo15394-sec-0032}
==========

Main findings {#bjo15394-sec-0033}
-------------

In this systematic review and meta‐analysis we aimed to provide a comprehensive overview of available evidence on cardiovascular disease after recurrent pre‐eclampsia. We found that women with recurrent pre‐eclampsia have a threefold increased risk of heart failure, two‐ to three‐fold risk of hypertension and IHD and almost a two‐fold risk of CVA and overall CVD, when compared with women with a single event of pre‐eclampsia and subsequent uncomplicated pregnancies. Although the set‐up, size and quality of studies were variable, our pooled analysis indicated that the overall association between recurrent pre‐eclampsia and CVD is a robust finding. As women with a history of pre‐eclampsia have been shown to be at increased risk of CVD, this identifies a subgroup of women who are at even greater risk and could benefit from early preventive measures.

Strengths and limitations {#bjo15394-sec-0034}
-------------------------

This systematic review provides an overview of all available evidence up until June 2017. As most evidence on the risk of CVD after recurrent pre‐eclampsia is based on small groups of women, the only way to obtain reliable results is by performing a meta‐analysis. A random‐effects model was used to incorporate between‐study variation. We only included studies in which pre‐eclampsia was clearly defined, leading to a clear and consistent additional risk of CVD in later life based on recurrence of this disease.

This study also has some limitations which need to be addressed. First, included studies date back to the 1970s and show a wide range of methodological quality. Only seven of 22 studies achieved the maximum score on the Newcastle--Ottawa Scale. Therefore, caution is needed when interpreting the results. Second, comparability between included studies is limited as definitions for exposure, outcome and effect measure differ. Consequently few data could be used for meta‐analysis, possibly resulting in an over‐ or under‐estimating of the risk when patient characteristics differ between and within studies. The small number of studies and the large population size of the main studies instantly lead to a higher heterogeneity in the meta‐analysis.[42](#bjo15394-bib-0042){ref-type="ref"} Also, different measurement of outcome, adjusting for confounders and duration of follow up, can lead to more variation than is to be expected. It could be argued that the addition of meta‐analysis from a relatively small number of studies is not likely to improve accuracy in the effect estimates when findings are consistent within the studies, but does illustrate the continuing need for better original data. Third, we identified several studies in which analysis of recurrence of pre‐eclampsia and development of CVD should be possible given the design of the study but was not mentioned in the paper. We experienced a low response rate to multiple emails to authors, hindering our inclusion of more studies. We speculate that it may be possible that some groups looked at this association, but found relatively small groups and minor correlations that were not important enough to mention, possibly leading to a form of publication bias. We believe it would be beneficial if more studies included recurrence of pre‐eclampsia in their work to allow for improvement of our pooled estimated in the future. Finally, the larger registry‐based studies used registered ICD codes upon discharge as outcome for hypertension and CVD.[21](#bjo15394-bib-0021){ref-type="ref"}, [22](#bjo15394-bib-0022){ref-type="ref"}, [23](#bjo15394-bib-0023){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"} As the development of CVD and specifically hypertension does not always require hospitalisation, it is possible that only the most severe cases have been included, possibly leading to selection bias.

Interpretation {#bjo15394-sec-0035}
--------------

Several reviews and meta‐analyses discuss the risk of CVD after pregnancy complications.[3](#bjo15394-bib-0003){ref-type="ref"}, [4](#bjo15394-bib-0004){ref-type="ref"}, [6](#bjo15394-bib-0006){ref-type="ref"}, [43](#bjo15394-bib-0043){ref-type="ref"} Only a few discuss recurrence as a factor, usually stating a higher risk of CVD based on one or two studies. Mechanisms explaining the relation of CVD and pre‐eclampsia are thought to be multifactorial. Several large studies have shown pre‐eclampsia to be an independent risk factor when correcting for several established cardiovascular risk markers, such as hypertension.[3](#bjo15394-bib-0003){ref-type="ref"} The significant correlation between pre‐eclampsia, recurrence and the development of hypertension, results in our hypothesis that hypertension does not solely explain the association. We have yet to elucidate whether (recurrent) pre‐eclamptic pregnancies induce metabolic and cardiovascular changes or if these women have a stronger predisposition for CVD.[21](#bjo15394-bib-0021){ref-type="ref"}, [22](#bjo15394-bib-0022){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"}, [39](#bjo15394-bib-0039){ref-type="ref"}

Other mechanisms that potentially plays a role in pre‐eclampsia and CVD are of an inflammatory nature with chronic inflammatory risk markers being significantly higher in former pre‐eclampsia patients.[6](#bjo15394-bib-0006){ref-type="ref"}, [44](#bjo15394-bib-0044){ref-type="ref"} Pre‐eclampsia and CVD also share other pathological features indicating similar pathways such as the presence of acute atherosis and endothelial cell dysfunction.[45](#bjo15394-bib-0045){ref-type="ref"}, [46](#bjo15394-bib-0046){ref-type="ref"} All of the above strengthens the idea that pregnancy can be seen as a 'stress test' for cardiovascular health, identifying women at risk early in life.

Women with an early onset and/or severe pre‐eclampsia are more likely to experience recurrence of disease compared with those who developed pre‐eclampsia at term.[7](#bjo15394-bib-0007){ref-type="ref"}, [8](#bjo15394-bib-0008){ref-type="ref"} Several studies found a consistently higher risk of cardiovascular morbidity and mortality when pre‐eclampsia was early in onset or when combined with (iatrogenic) preterm birth or other complications like fetal growth restriction, irrespective of recurrence of pre‐eclampsia.[21](#bjo15394-bib-0021){ref-type="ref"}, [23](#bjo15394-bib-0023){ref-type="ref"}, [25](#bjo15394-bib-0025){ref-type="ref"} In one study from Riise et al.,[23](#bjo15394-bib-0023){ref-type="ref"} a steadily increasing risk of cardiovascular death after recurrent pre‐eclampsia was found with higher hazard ratios when (recurrent) pre‐eclampsia concurred with preterm delivery or fetal growth restriction. Unfortunately, there were no studies in which data on severity, time of onset and recurrence could be extracted for meta‐analysis.[3](#bjo15394-bib-0003){ref-type="ref"}, [33](#bjo15394-bib-0033){ref-type="ref"} Therefore, we cannot infer from our review to what extent the association between recurrent pre‐eclampsia and CVD is explained by the onset and/or severity of the first episode.

Several studies within this review discussed timing as a factor in determining cardiovascular risk, morbidity and mortality. When looking at cardiovascular risk markers, studies found significant correlation after many years of follow up, even though these markers may not be apparent soon after pregnancy.[27](#bjo15394-bib-0027){ref-type="ref"}, [28](#bjo15394-bib-0028){ref-type="ref"}, [30](#bjo15394-bib-0030){ref-type="ref"}, [31](#bjo15394-bib-0031){ref-type="ref"}, [32](#bjo15394-bib-0032){ref-type="ref"}, [35](#bjo15394-bib-0035){ref-type="ref"}, [37](#bjo15394-bib-0037){ref-type="ref"}, [40](#bjo15394-bib-0040){ref-type="ref"} A few studies analysed time between pre‐eclampsia and CVD in their set‐up, reporting a significantly shorter time to cardiovascular events in the recurrent group with a significantly accelerated disease progression. The magnitude of this time‐specific association appears to decrease over time but remained significant when comparing recurrent and nonrecurrent pre‐eclampsia.[20](#bjo15394-bib-0020){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"} Several studies have shown that hypertension is present shortly after pre‐eclampsia.[47](#bjo15394-bib-0047){ref-type="ref"}, [48](#bjo15394-bib-0048){ref-type="ref"} After a longer latency period, age‐specific risk factors might play a more prominent role and risk for hypertension and CVD in women with normotensive subsequent pregnancies will become more alike. However, studies with a longer follow up still showed significant increased risk in the recurrent group**.** [21](#bjo15394-bib-0021){ref-type="ref"}, [26](#bjo15394-bib-0026){ref-type="ref"}, [41](#bjo15394-bib-0041){ref-type="ref"} Some studies mention the high risk of having had pre‐eclampsia among women having only one pregnancy. Possibly, women with the most severe form of pre‐eclampsia refrain from subsequent pregnancies because of older age or perceived risk, preventing a dose--response type relationship from becoming apparent.[23](#bjo15394-bib-0023){ref-type="ref"}, [25](#bjo15394-bib-0025){ref-type="ref"} There were several studies in our systematic search that did not specify the type of hypertensive pregnancy disorders and were therefore not included in this review. Interestingly, they report that women with recurrent gestational hypertension (including pre‐eclampsia) have a similar increased risk of CVD.[49](#bjo15394-bib-0049){ref-type="ref"}, [50](#bjo15394-bib-0050){ref-type="ref"}, [51](#bjo15394-bib-0051){ref-type="ref"}, [52](#bjo15394-bib-0052){ref-type="ref"}, [53](#bjo15394-bib-0053){ref-type="ref"}, [54](#bjo15394-bib-0054){ref-type="ref"}

Conclusion {#bjo15394-sec-0036}
==========

Evidence shows a strong relationship between recurrence of pre‐eclampsia and additional risk of developing hypertension and CVD later in life compared with a single pregnancy with pre‐eclampsia. With the increasing burden of CVD on society, this needs to be taken into consideration when establishing prevention programmes. This review shows that multiple complicated pregnancies may need to be weighed more heavily, compared with when subsequent pregnancies were normotensive.
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